With the firm indicated as closed in 2020, Compound Therapeutics - biotechnology company developing a new generation of high-potency targeted protein-based drugs - confirmed its acquisition of strategic assets of Phylos. Phylos, Inc. had been a privately held biotechnology founded to apply the principles of in vitro selection and evolution to peptides and proteins. Anchored in work undertaken at Massachusetts General Hospital and licensed exclusively to Phylos, the plan wasindicated as application of this technology to improve existing proteins and to develop of alternatives to such proteins falling outside the scope of existing patent protection. Phylos was indicated as poised to exploit opportunities for directed protein evolution and the detection of protein-protein interactions across a broad spectrum of commercial applications, including those in the pharmaceutical, diagnostic, agricultural, chemical, and food processing industries.
